A randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ Cancer Receiving Treatment with Primary Radiation Therapy

Detalle

A randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ Cancer Receiving Treatment with Primary Radiation Therapy. Protocol 56021927PCR3003; Phase 3. EudraCT Number: 2015-003007-38. Aproved 14 July 2015. EDMS number: EDMS-ERI-98365794; 1.0. Investigador Principal.